Premium
Clinical significance of p53, nm23, and bcl‐2 in T 3–4 N 1 M 0 oesophageal carcinoma: An immunohistochemical approach
Author(s) -
Patel Devendra D.,
Bhatavdekar Jyotsna M.,
Chikhlikar Priya R.,
Patel Yatin V.,
Shah Neelam G.,
Ghosh Nandita,
Suthar Tejal P.,
Balar Damodar B.
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199706)65:2<111::aid-jso7>3.0.co;2-a
Subject(s) - immunohistochemistry , medicine , immunostaining , carcinoma , p53 protein , univariate analysis , p53 expression , pathology , cancer , clinical significance , gastroenterology , multivariate analysis
Background and Objective The purpose of this retrospective study was to test whether the expression of p53, nm23, and bcl‐2 in T 3–4 N 1 M 0 oesophageal carcinoma is associated with patient survival. Methods Immunohistochemical localisation of p53, nm23, and bcl‐2 was performed on formalin‐fixed, paraffin‐embedded tissue sections (N = 46). The observed range of follow‐up period was 0.2–24.0 months with a median of 11.0 months. A total of 85% (39/46) of the patients died within 24.0 months, which could be due to advanced disease at presentation. The immunohistochemical signal was expressed as the proportion of positive cells. The immunostaining for p53 was nuclear, whereas that for nm23 and bcl‐2 was cytoplasmic in the neoplastic cells. Results p53 was expressed in 70% (32/46) of cases; nm23 in 29% (13/45), and bcl‐2 in 67% (29/43) of tumours. The univariate analysis showed that the expression of two markers, i.e., expression of p53 and absence of nm23 were independently associated with unfavourable overall survival time. Despite a small number of patients treated with adjuvant therapy, we observed that tumours positive for p53 had an unfavourable prognosis when compared with tumours negative for p53. Conclusions Our preliminary findings suggest: expression of p53 and nm23 negativity may be related to an unfavourable prognosis in patients with advanced oesophageal carcinoma. J. Surg. Oncol. 1997;65:111–116. © 1997 Wiley‐Liss, Inc.